Daniel Gallo
Chief Tech/Sci/R&D Officer bei ZEVRA THERAPEUTICS, INC.
Profil
Daniel Gallo is currently the Senior Vice President-Medical Affairs & Advocacy at Zevra Therapeutics, Inc. He previously worked as the Vice President & Head-Medical Affairs at Jaguar Gene Therapy LLC.
Gallo earned a doctorate degree from Northwestern University.
Aktive Positionen von Daniel Gallo
| Unternehmen | Position | Beginn |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31.01.2023 |
Ehemalige bekannte Positionen von Daniel Gallo
| Unternehmen | Position | Ende |
|---|---|---|
Jaguar Gene Therapy LLC
 Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Daniel Gallo
| Northwestern University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | Health Services |
